Esther Heijnen
Overview
Explore the profile of Esther Heijnen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jastorff A, Gymnopoulou E, Salas J, Merrall E, Buntinx E, Martin C, et al.
Vaccine
. 2024 Nov;
43(Pt 1):126514.
PMID: 39536455
Background: Respiratory syncytial virus (RSV) causes a significant disease burden in adults with chronic comorbidities. Rates of severe RSV disease and death are as high, or higher in younger adults...
2.
van Heesbeen R, Bastian A, Omoruyi E, Rosen J, Comeaux C, Callendret B, et al.
Vaccine
. 2024 Sep;
42(26):126273.
PMID: 39276619
Background: Respiratory syncytial virus (RSV) can cause severe illness in older adults. A combination vaccine containing Ad26.RSV.preF and purified recombinant RSV preF protein has previously demonstrated efficacy and tolerability in...
3.
Langley J, Nolan T, Ramet M, Richmond P, Rosario Filho N, Haazen W, et al.
Open Forum Infect Dis
. 2024 Sep;
11(9):ofae453.
PMID: 39220658
Background: Respiratory syncytial virus (RSV) causes serious illness in children. The Ad26.RSV.preF vaccine candidate was immunogenic with acceptable safety in a phase 1/2a study of RSV-seropositive children. Here, we assessed...
4.
Jastorff A, Bastian A, Ligtenberg N, Klyashtornyy V, Callendret B, Heijnen E
Hum Vaccin Immunother
. 2024 Aug;
20(1):2383504.
PMID: 39118413
The Ad26.RSV.preF/RSV preF protein vaccine has previously demonstrated efficacyin protecting older adults against respiratory syncytial virus (RSV)-related lower respiratory tract disease in a phase 2b study. This study compared the...
5.
Falsey A, Hosman T, Bastian A, Vandenberghe S, Chan E, Douoguih M, et al.
Lancet Infect Dis
. 2024 May;
24(9):1015-1024.
PMID: 38801826
Background: Ad26.RSV.preF-RSV preF protein showed 80·0% vaccine efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in older adults during one RSV season. No RSV vaccines have shown...
6.
Hosman T, van Heesbeen R, Bastian A, Hu W, Comeaux C, Ligtenberg N, et al.
Hum Vaccin Immunother
. 2024 May;
20(1):2344970.
PMID: 38783590
This study assessed three Ad26.RSV.preF/RSV preF protein combinations, combining different Ad26.RSV.preF doses and naturally aged preF protein, representing the expected critical vaccine quality attributes close to release, around intermediate shelf-life...
7.
Widagdo W, Bastian A, Jastorff A, Scheys I, De Paepe E, Comeaux C, et al.
J Infect Dis
. 2023 Dec;
230(2):e374-e383.
PMID: 38134393
Background: Since influenza and respiratory syncytial virus (RSV) carry significant burden in older adults with overlapping seasonality, vaccines for both pathogens would ideally be coadministered in this population. Here we...
8.
Bartsch Y, Cizmeci D, Yuan D, Mehta N, Tolboom J, De Paepe E, et al.
J Virol
. 2023 Oct;
97(11):e0077123.
PMID: 37902399
Respiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness...
9.
Comeaux C, Bart S, Bastian A, Klyashtornyy V, De Paepe E, Omoruyi E, et al.
J Infect Dis
. 2023 Jul;
229(1):19-29.
PMID: 37433021
Background: Ad26.RSV.preF is an adenovirus serotype 26 vector-based respiratory syncytial virus (RSV) vaccine encoding a prefusion conformation-stabilized RSV fusion protein (preF) that demonstrated robust humoral and cellular immunogenicity and showed...
10.
Osborne R, Nelson L, Fehnel S, Williams N, Bender R, Ziemiecki R, et al.
J Patient Rep Outcomes
. 2023 Jun;
7(1):51.
PMID: 37261682
Background: The Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) is a patient-reported outcome measure designed to assess symptoms and impacts of respiratory syncytial virus (RSV) infection. This study evaluated the...